Stock Fundamentals

Company Information

Company Name
Arcus Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
ISIN: US03969F1093
CIK: 0001724521
CUSIP: 03969F109
Currency: USD
Full Time Employees: 601
Phone: 510 694 6200
Fiscal Year End: December
IPO Date: Mar 15, 2018
Description:

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Address:

3928 Point Eden Way, Hayward, CA, United States, 94545

Directors & Officers

Name Title Year Born
Dr. Terry J. Rosen Ph.D. Co-Founder, Chairman & CEO 1960
Dr. Juan Carlos Jaen Ph.D. Co- Founder & President 1958
Mr. Robert C. Goeltz II Principal Financial Officer & CFO 1973
Ms. Jennifer A. Jarrett M.B.A. Advisor 1971
Dr. Richard A. Markus M.D., Ph.D. Chief Medical Officer NA
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Mr. Alexander Azoy CPA Chief Accounting Officer 1976
Dr. Jonathan Yingling Ph.D. Chief Scientific Officer 1969
Pia Eaves Vice President of Investor Relations & Strategy NA
Ms. Carolyn C. Tang J.D. General Counsel & Corporate Secretary 1979

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 05, 2026 Juan C Jaen N/A Sale 31.82K $21.41 $681.33K
Dec 31, 2025 Robert C Goeltz II N/A Sale 6.55K $23.38 $153.19K
Dec 18, 2025 Alexander Azoy N/A Sale 4.34K $22.25 $96.63K
Dec 17, 2025 Alexander Azoy N/A Sale 2.11K $22.16 $46.82K
Dec 17, 2025 Carolyn C Tang N/A Sale 6.81K $22.16 $150.91K
Dec 17, 2025 Jennifer Jarrett N/A Sale 9.98K $22.16 $221.22K
Dec 17, 2025 Juan C Jaen N/A Sale 9.98K $22.16 $221.22K
Dec 17, 2025 Richard Markus N/A Sale 4.49K $22.16 $99.59K
Dec 17, 2025 Robert C Goeltz II N/A Sale 5.96K $22.16 $132.07K
Dec 17, 2025 Terry J Rosen N/A Sale 25.74K $22.16 $570.49K
Dec 16, 2025 Richard Markus N/A Sale 5.05K $21.88 $110.54K
Dec 16, 2025 Terry J Rosen N/A Sale 28.95K $21.88 $633.36K
Dec 16, 2025 Robert C Goeltz II N/A Sale 6.70K $21.88 $146.64K
Dec 16, 2025 Juan C Jaen N/A Sale 11.23K $21.88 $245.60K
Dec 16, 2025 Jennifer Jarrett N/A Sale 11.23K $21.88 $245.60K
Dec 16, 2025 Carolyn C Tang N/A Sale 7.66K $21.88 $167.56K
Dec 16, 2025 Alexander Azoy N/A Sale 2.38K $21.88 $51.99K
Dec 04, 2025 Juan C Jaen N/A Sale 83.00K $24.71 $2.05M
Nov 26, 2025 Alexander Azoy N/A Sale 1.90K $26.00 $49.40K
Nov 18, 2025 Juan C Jaen N/A Sale 5.05K $19.75 $99.74K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 15.23M Mar 31, 2026 12.11% $0.01 1.52%
Vanguard Group Inc 7.96M Dec 31, 2025 6.33% $0.00 20.11%
Wellington Management Company LLP 6.09M Mar 31, 2026 4.84% $0.02 17.46%
State Street Corp 5.41M Mar 31, 2026 4.30% $0.00 18.26%
Suvretta Capital Management, LLC 5.03M Mar 31, 2026 4.00% $2.78 -3.04%
Woodline Partners LP 3.78M Mar 31, 2026 3.00% $0.31 0.21%
Marshall Wace Asset Management Ltd 3.76M Mar 31, 2026 2.99% $0.08 11.03%
Siren, L.L.C. 3.01M Mar 31, 2026 2.39% $1.80 0.00%
Geode Capital Management, LLC 2.25M Mar 31, 2026 1.79% $0.00 18.09%
Fisher Asset Management, LLC 2.19M Mar 31, 2026 1.74% $0.02 12.34%
Samlyn Capital, LLC 1.91M Mar 31, 2026 1.52% $0.70 18.96%
BNP Paribas Investment Partners SA 1.65M Mar 31, 2026 1.32% $0.04 -1.93%
Dimensional Fund Advisors, Inc. 1.43M Mar 31, 2026 1.13% $0.01 -6.43%
Citadel Advisors Llc 1.33M Mar 31, 2026 1.06% $0.00 1,170.22%
Parkman Healthcare Partners LLC 1.21M Mar 31, 2026 0.96% $2.69 24.64%
Logos Global Management LP 1.20M Mar 31, 2026 0.95% $1.29 0.00%
FMR Inc 1.17M Mar 31, 2026 0.93% $0.00 2.65%
Morgan Stanley - Brokerage Accounts 1.11M Mar 31, 2026 0.89% $0.00 -8.03%
Trails Edge Capital Partners, LP 1.05M Mar 31, 2026 0.83% $5.19 14.36%
The Goldman Sachs Group Inc 999.79K Mar 31, 2026 0.79% $0.00 -14.43%

Shares Statistics

Shares Outstanding: 125.77M
Shares Float: 89.09M
% Insiders: 2,912.70%
% Institutions: 7,241.90%
Short % Float: 14.24%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 5.17M 4.11% ▲ 0.02% Apr 30, 2026
2 Vanguard Health Care Inv 4.12M 3.28% ▲ 28.68% Mar 31, 2026
3 Vanguard Total Stock Mkt Idx Inv 2.83M 2.25% ▲ 0.39% Apr 30, 2026
4 State Street® SPDR® S&P® Biotech ETF 2.42M 1.92% ▼ 0.71% Apr 30, 2026
5 iShares Russell 2000 ETF 1.98M 1.57% ▲ 0.85% Apr 30, 2026
6 Vanguard Small Cap Index 1.01M 0.80% ▼ 0.43% Apr 30, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 955.57K 0.76% ▲ 0.89% Apr 30, 2026
8 BNP Paribas US Small Cap ClassicC 944.75K 0.75% ▼ 4.71% Mar 31, 2026
9 Belfius Equities Cure C Cap 926.12K 0.74% ▲ 0.00% Nov 30, 2025
10 Fidelity Select Biotechnology 831.10K 0.66% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $2.52B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $3.08B
EBITDA: $-389.00M
Book Value: $4.18
Earnings/Share: $-3.17
Profit Margin: -156.36%
Operating Margin: -788.24%
ROA (TTM): -23.11%
ROE (TTM): -69.95%
Revenue (TTM): $236.00M
Revenue/Share (TTM): $2.07
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -39.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.36x 0.16x 0.45x -48.25x -0.30x
2024-12-31 4.50x 0.12x 0.58x -82.50x -0.22x
2023-12-31 4.52x 0.02x 0.58x -170.00x -0.04x
2022-12-31 5.52x 0.00x 0.51x -140.00x -0.01x
2021-12-31 7.60x 0.01x 0.47x 207.69x 0.09x
2020-12-31 6.05x 0.01x 0.35x N/A -0.02x
2019-12-31 8.49x 0.06x 0.19x N/A -0.11x
2018-12-31 15.29x 0.03x 0.15x -11.15x -0.12x
2017-12-31 13.90x 0.02x 0.19x N/A -0.06x
2016-12-31 17.98x 0.00x 0.09x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about RCUS.US!